

# R&D Fact Sheet

**We are AbbVie**, a research-based global biopharmaceutical company. AbbVie Research and Development (R&D) has built a robust portfolio and pipeline of innovative medicines that raise the standard of care for serious diseases.

Our mission: discover and develop transformative therapies that deliver compelling patient benefits, strong clinical performance and clear economic value, while reshaping the standard of care for patients.


## Our Pipeline

AbbVie has a robust pipeline. Globally, there are approximately **1.5 billion** people living with conditions that AbbVie's pipeline aims to treat.



**150 Million+**

Potential patients live in the U.S.



## Focus Areas

We focus on discovering, developing, and delivering drugs in therapeutic areas where we have proven expertise and where we can have an impact. These areas include:

- Oncology**
    - Evaluating **20+ experimental medicines** for more than **20 different types of solid tumors and blood cancers**
    - Conducting **200+ clinical trials in 49 different countries** around the world
  - Immunology**
    - **15+ new molecules** being evaluated, with **two treatments in late-stage studies** for immune-mediated conditions
    - Leveraging deep scientific expertise to develop next-generation biologics and small molecules that elevate standard of care
  - Neuroscience**
    - Focused on diseases with the highest unmet need including Alzheimer's disease, Parkinson's disease, multiple sclerosis and Progressive Supranuclear Palsy (PSP)
    - Using novel technologies, including imaging and biomarkers, to study the most promising areas of disease biology to develop strategies that directly target disease pathology
    - Currently conducting **two Phase 2 clinical studies** of our investigational anti-tau therapy in Alzheimer's disease and PSP
  - Virology**
    - Pursuing pangenotypic regimens to address remaining unmet need for patients living with chronic HCV
- **60+ active clinical development programs** across our key therapeutic areas
  - By 2020, deliver **20+ new medicines to patients** or secure significant approvals for current medicines in other stages of diseases in our areas of focus

## Behind the Science

AbbVie is investing in groundbreaking science and innovative technology in order to generate the insights necessary to fuel our pipeline and deliver a new wave of medicines.

### Key technologies and platforms include:



**Bispecifics**



**Antibody drug conjugates**



**Targeting cancer stem cells**



**Nanoparticles & Protein capsules**



**Immuno-oncology & immunotherapies**

For an overview of our latest pipeline, please visit: [www.abbvie.com/our-science/pipeline](http://www.abbvie.com/our-science/pipeline)

## Where We Operate

With more than **8,000+ R&D employees** at work today, AbbVie's innovation is driven by leading scientists and facilities. With a large presence around the world, AbbVie has 8 state-of-the-art R&D research centers and 14 manufacturing centers.

### Key Research centers include:



## Partnership Strategy

Our partners share our commitment to solving the world's greatest health needs.

### That's why we collaborate with:



**Peers**



**Universities**



**Clinical Experts**



**Governments**



**Advocacy Groups**

These collaborations allow us to seek new solutions for patients throughout the world. By working together, we combine the best efforts, thinking and resources to find better solutions for patients.

As we continue to develop innovative treatments across our portfolio, we remain committed to working collaboratively with the best and smartest minds to raise the standard of care for serious diseases, together.